Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primarytumor and its lymph node metastases

Prostate

Volumn 69, Issue 4, 2009, Pages 352-362

  Fleischmann, Achim ^a   Schobinger, Sylviane ^a   Schumacher, Martin ^a   Thalmann, George N ^a   Studer, Urs E ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Lymph node metastases; Lymphadenectomy; Prognosis; Prostate cancer; Prostatectomy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MICROMETASTASIS; MULTIVARIATE ANALYSIS; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; FOLLOW UP; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; PROSTATE TUMOR; RISK FACTOR; TREATMENT OUTCOME;

AGED; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 59849098251     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20889     Document Type: Article

References (38)

1. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996;20(3):286-292.
2. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167(2):528-534.
3. Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001;91(1):66-73.
4. Swanson GP, Thompson IM, Basler J. Current status of lymph node-positive prostate cancer: Incidence and predictors of outcome. Cancer 2006;107(3):439-450.
5. Cheng L, Bergstralh EJ, Cheville JC, Slezak J, Corica FA, Zincke H, Blute ML, Bostwick DG. Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol 1998;22(12):1491 -1500.
6. Cheng L, Slezak J, Bergstralh EJ, Cheville JC, Sweat S, Zincke H, Bostwick DG. Dedifferentiation in the metastatic progression of prostate carcinoma. Cancer 1999;86(4):657-663.
7. ChengL,DarsonMF,BergstralhEJ,SlezakJ,MyersRP,Bostwick DG. Correlation of margin status and extraprostatic extension with progression of prostate carcinoma. Cancer 1999;86(9):1775-1782.
8. Cheng L, Pisansky TM, Ramnani DM, Leibovich BC, Cheville JC, Slezak J, Bergstralh EJ, Zincke H, Bostwick DG. Extranodal extension in lymph node-positive prostate cancer. Mod Pathol 2000;13(2):113-118.
9. Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, Skinner EC, Skinner DG. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: Long-term results. J Urol 2004;172(6):2252- 2255.
10. Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002;168(2):514-518.
11. Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169(3):849-854.
12. Palapattu GS, Allaf ME, Trock BJ, Epstein JI, Walsh PC. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: Results of long-term follow-up. J Urol 2004;172(5):1860-1864.
13. Sgrignoli AR, Walsh PC, Steinberg GD, Steiner MS, Epstein JI. Prognostic factors in men with stage D1 prostate cancer: Identification of patients less likely to have prolonged survival after radical prostatectomy. J Urol 1994;152(4):1077-1081.
14. Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Berg-stralh EJ, Karnes RJ, Frank I, Blute ML. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 2007;178(3):864-871.
15. Sobin LH, Wittekind C, editors. TNM Atlas. 6th edition. New York: Wiley-Lyss, Inc; 2002.
16. Frazier HA II, Robertson JE, Paulson DF. Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival? World J Urol 1994;12(6):308-312.
17. Epstein JI, Algaba F, Allsbrook WC Jr, Bastacky S, Boccon-Gibod L, De Marzo AM, Egevad L, Furusato M, Hamper UM, Helpap B, Humphrey PA, Iczkowski KA, Lopez-Beltran A, Montironi R, Rubin MA, Sakr WA, Samaratunga H, Parkin DM. Acinar adenocarcinoma. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. World heath organisation classification of tumours pathology and genetics tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004. pp 162-198.
18. Sakr WA, Grignon DJ, Visscher DW, Wolman SR, Crissman JD. Evaluating the radical prostatectomy specimen, part I. J Urol Pathol 1995;3:355-364.
19. Jakobsen J, Hansen O, Jorgensen KE, Bastholt L. Lymph node metastases from laryngeal and pharyngeal carcinomas-Calculation of burden of metastasis and its impact on prognosis. Acta Oncol 1998;37(5):489-493.
20. Epstein JI, Srigley J, Grignon D, Humphrey P. Recommendations for the reporting of prostate carcinoma. Hum Pathol 2007;38(9):1305-1309.
21. Epstein JI, Amin M, Boccon-Gibod L, Egevad L, Humphrey PA, Mikuz G, Newling D, Nilsson S, Sakr W, Srigley JR, Wheeler TM, Montironi R. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenec-tomy specimens. Scand J Urol Nephrol Suppl 2005;216:34-63.
22. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, Di'santagnese PA, Trump D. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lympha-denectomy. Lancet Oncol 2006;7(6):472-479.
23. Zwergel U, Lehmann J, Wullich B, Schreier U, Remberger K, Zwergel T, Stoeckle M. Lymph node positive prostate cancer: Long-term survival data after radical prostatectomy. J Urol 2004;171(3):1128-1131.
24. Burkhard FC, Studer UE. The role of lymphadenectomy in prostate cancer. Urol Oncol 2004;22(3):198-202.
25. Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006;68(1):121-125.
26. Gofrit ON, Zorn KC, Steinberg GD, Zagaja GP, Shalhav AL. The Will Rogers phenomenon in urological oncology. J Urol 2008;179(1):28-33.
27. Weingartner K, Ramaswamy A, Bittinger A, Gerharz EW, Voge D, Riedmiller H. Anatomical basis for pelvic lymphadenectomy in prostate cancer: Results of an autopsy study and implications for the clinic. J Urol 1996;156(6):1969-1971.
28. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341(24):1781 -1788.
29. Bochner BH, Herr HW, Reuter VE. Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. J Urol 2001;166(6):2295-2296.
30. Brawn P, Kuhl D, Johnson C III, Pandya P, McCord R. Stage D1 prostate carcinoma. The histologic appearance of nodal meta-stases and its relationship to survival. Cancer 1990;65(3):538-543.
31. Bazinet M, Hamdy SM, Begin LR, Stephenson RA, Fair WR. Prognostic significance of antigenic heterogeneity, Gleason grade, and ploidy of lymph node metastases in patients with prostate cancer. Prostate 1992;20(4):311 -326.
32. Hofer MD, Kuefer R, Huang W, Li H, Bismar TA, Perner S, Hautmann RE, Sanda MG, Gschwend JE, Rubin MA. Prognostic factors in lymph node-positive prostate cancer. Urology 2006;67(5):1016-1021.
33. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351(2):125-135.
34. Patel DA, Presti JC Jr, McNeal JE, Gill H, Brooks JD, King CR. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 2005;23(25)6157-6162.
35. Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005;174(6):2191 -2196.
36. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294(4):433-439.
37. Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T. EZH2, Ki-67, and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 2008;122(3):595-602.
38. Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ, Dutta A. Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res 1996;56(18):4159-4163.